Carl Gordon
Chairman at KEROS THERAPEUTICS, INC.
Net worth: 13 865 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jing Rong Cui | M | 60 |
Blossomhill Therapeutics, Inc.
 Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | 8 years |
| Yi Shan Li | M | 59 |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | 11 years |
| Vered Bisker-Leib | M | 53 | 7 years | |
| Iain Dukes | M | 65 |
Gwynant Therapeutics
 Gwynant Therapeutics Pharmaceuticals: MajorHealth Technology Gwynant Therapeutics develops new small molecules for oncology targets.
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 8 years |
| Stephen P. Squinto | M | 67 |
Emendo Biotherapeutics, Inc.
 Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 8 years |
| Nima Farzan | M | 48 | 4 years | |
| Erin Quirk | M | 53 | 5 years | |
| Jason Meyenburg | M | 47 |
Gemini Therapeutics Sub, Inc.
 Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | 5 years |
| Jacob Chacko | M | 45 | 6 years | |
| Hong Bo Lu | M | 53 |
OrbiMed Advisors LLC
 OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds. | 13 years |
| Arnon Rosenthal | M | 68 | 11 years | |
| David Lubner | M | 60 |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | 4 years |
| Gary D. Glick | M | - |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | - |
| Adam Rosenthal | M | - |
Star Therapeutics, Inc.
 Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation.
Electra Therapeutics, Inc.
 Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | - |
| Richard Scheller | M | 70 | 9 years | |
| Chen Schor | M | 51 | 8 years | |
| Qing Dong | M | - |
Xinthera, Inc.
 Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The private company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | 3 years |
| Bradford Dahms | M | 36 | 3 years | |
| Dhvanit Shah | M | - |
Garuda Therapeutics, Inc.
 Garuda Therapeutics, Inc. BiotechnologyHealth Technology Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation. | - |
| James Tananbaum | M | 60 |
Xinthera, Inc.
Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The private company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | 4 years |
| Mary Gray | M | 71 | 4 years | |
| Tu Yen Ong | M | 49 |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | 4 years |
| Bryan Yoon | M | 46 | 4 years | |
| Sheila Gujrathi | M | 53 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 7 years |
| Saqib Islam | M | 54 | 7 years | |
| Yi Liu | M | 56 |
Kumquat Biosciences, Inc.
 Kumquat Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Kumquat Biosciences, Inc. provides biotechnology services. The company was founded by Yi Liu and Pingda Ren and is headquartered in San Diego, CA. | 6 years |
| Danielle Pasqualone | M | - | 5 years | |
| Jason Rhodes | M | 54 |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | 8 years |
| David Fellows | M | 67 | 4 years | |
| Pingda Ren | M | 55 |
Kumquat Biosciences, Inc.
Kumquat Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Kumquat Biosciences, Inc. provides biotechnology services. The company was founded by Yi Liu and Pingda Ren and is headquartered in San Diego, CA. | 6 years |
| Richard DiMarchi | M | 71 |
MBX Biosciences, Inc.
 MBX Biosciences, Inc. Electronic Equipment/InstrumentsElectronic Technology MBX Biosciences, Inc. operates as a preclinical-stage biotech company. It creates therapies to treat rare endocrine diseases. The company was founded by Peter Kent Hawryluk and Timothy Knickerbocker and is headquartered in Carmel, IN. | 6 years |
| Frank Verwiel | M | 62 | 7 years | |
| Louis Lavigne | M | 75 | 6 years | |
| Geoffrey Hsu | M | - |
OrbiMed Advisors LLC
OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 22 years |
| Paul Hastings | M | 64 | 13 years | |
| Darren J. Carroll | M | - | 6 years | |
| Alpna Seth | M | 60 | 1 years | |
| Ellen Chiniara | F | 65 | 2 years | |
| Yong Dai | M | 53 |
Frontera Therapeutics (HK) Ltd.
 Frontera Therapeutics (HK) Ltd. Pharmaceuticals: MajorHealth Technology Part of Frontera Therapeutics, Inc., Frontera Therapeutics (HK) Ltd. is a Chinese pharmaceutical company that manufactures pharmaceutical products. The private company was founded by Yong Dai and Yong Dai has been the CEO since incorporation. | - |
| Amy Burroughs | F | 54 | - | |
| Christian Nolet | M | 67 | 1 years | |
| Kim Diamond | F | - | 6 years | |
| Jon Stonehouse | M | 63 | 17 years | |
| Vivek Sivathanu | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 4 years |
| Jim Kastenmayer | M | 52 | 1 years | |
| Valerie Odegard | M | 46 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | 2 years |
| Jeffrey Kindler | M | 68 | 4 years | |
| Alan Fuhrman | M | 67 | 5 years | |
| Ann Taylor | M | 67 | 3 years | |
| Esther Cho | F | - | 4 years | |
| Kipyegon Kitur | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 6 years |
| Jonathan Mandelbaum | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 4 years |
| Karen Wong | F | - |
Kumquat Biosciences, Inc.
Kumquat Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Kumquat Biosciences, Inc. provides biotechnology services. The company was founded by Yi Liu and Pingda Ren and is headquartered in San Diego, CA. | 6 years |
| Katie Peng | F | - | 1 years | |
| Klaus Veitinger | M | 62 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 17 years |
| Scott Lipman | M | - | 4 years | |
| Kathy Dong | M | - |
Electra Therapeutics, Inc.
Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | 1 years |
| Steve Dubin | M | 70 | 4 years | |
| Freda Lewis-Hall | M | 69 | 7 years | |
| Scotland Stevens | M | - |
OrbiMed Advisors LLC
OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 19 years |
| Jill Quigley | F | 49 | 4 years | |
| Richard Lindahl | M | 70 | 1 years | |
| Angie You | M | 51 | 3 years | |
| Brian Harvey | M | 63 | 4 years | |
| Michael Kauffman | M | 60 | 3 years | |
| Mardi Dier | F | 60 | 4 years | |
| Lori Kunkel | M | 66 | 4 years | |
| Trevor M. Polischuk | M | - |
OrbiMed Advisors LLC
OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 21 years |
| David Bonita | M | 48 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 20 years |
| Andrew Sinclair | M | 52 | 3 years | |
| Rishi Gupta | M | 46 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 21 years |
| Phil Ferneau | M | 62 | 9 years | |
| James Boylan | M | 57 | 2 years | |
| Radhika Tripuraneni | M | 44 | 2 years | |
| Carter Neild | M | - |
OrbiMed Advisors LLC
OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 23 years |
| Philip Reilly | M | - |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | - |
| Steven Hoerter | M | 53 | 3 years | |
| Brendan Weber | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 7 years |
| Mark Vignola | M | 47 | 4 years | |
| Philip Johnson | M | 59 | 6 years | |
| Sven Borho | M | 55 |
OrbiMed Advisors LLC
OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds. | 35 years |
| Jeffrey Chodakewitz | M | 68 | 4 years | |
| James Healy | M | 58 | 1 years | |
| Winston Kung | M | 48 | - | |
| David Wehner | M | 54 | 6 years | |
| Jonathan Anderman | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Tillman Gerngross | M | 60 |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | 13 years |
| Michael Gray | M | 53 |
Arsanis, Inc.
Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | 3 years |
| Athena Countouriotis | M | 52 | - | |
| Weidong Zhong | M | 58 | 4 years | |
| Georges Gemayel | M | 64 | - | |
| Joseph Zakrzewski | M | 60 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.
Arius Research, Inc.
 Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | 11 years |
| Mark Meltz | M | 50 | 4 years | |
| Lewis J. Shuster | M | 68 | 4 years | |
| Werner Cautreels | M | 71 | 8 years | |
| Stephen W. Kaldor | M | 62 | 3 years | |
| Paula Ragan | M | 54 |
Arsanis, Inc.
Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | - |
| Peter Svennilson | M | 62 | 7 years | |
| Peter van Vlasselaer | M | 64 | 8 years | |
| Michael Rome | M | 39 | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 92 | 92.00% |
| China | 15 | 15.00% |
| Canada | 1 | 1.00% |
| Hong Kong | 1 | 1.00% |
| Ireland | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Carl Gordon
- Personal Network